Ask AI
ProCE Banner Activity

CME

Next-Generation Approaches for Relapsed Refractory Multiple Myeloma: A Focus on Novel Therapeutic Targets and Pathways

Video

In this accredited on-demand webcast, experts discuss the emerging role of CELMoD agents in the treatment of relapsed/refractory multiple myeloma, highlighting their novel mechanisms of action and clinical efficacy, and how to integrate these therapies into current treatment paradigms to improve patient outcomes.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement to mutually recognize continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM  into European CME credit (ECMEC) should contact the UEMS (www.uems.eu). 

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: July 17, 2025

Expiration: January 16, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Describe the role and rationale for novel immunomodulatory mechanisms of action that are still under investigation as therapeutic options for patients with relapsed/refractory MM who may be resistant to previous therapies​

  • Evaluate the efficacy data as well as safety and tolerability profiles of investigational agents that target protein degradation pathways in MM treatment, including the potential clinical application in triple-class exposed MM​

  • Identify eligible patients with R/R MM for enrollment on ongoing clinical trials evaluating novel therapies targeting novel pathways with awareness of potential disparities in clinical trial enrollment in this patient population

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Michele Cavo, MD, has no relevant financial relationships to disclose.

Sagar Lonial, MD, FACP: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; other financial or material support: TG Therapeutics.

Charlotte Pawlyn, MB BChir, PhD: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Johnson & Johnson, Menarini, Opna Bio, Pfizer, Sanofi; researcher: Johnson & Johnson.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 17, 2025, through January 16, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.